Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | QPCT | Q16769 | 1/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | SNCA | P37840 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL1881161 | 0.90 | TAAR1 (0.48) | TAAR1LMNAQPCTCHEK1MEN1 | |
| Trifluoroacetic Acid SCHEMBL3038466 | 0.86 | EPHB4 (0.39) | — | |
| Trifluoroacetic Acid SCHEMBL3051554 | 0.84 | KDM4E (0.47) | QPCTL3MBTL1KMT2A | |
| Trifluoroacetic Acid SCHEMBL3051308 | 0.83 | HTR5A (0.44) | QPCT | |
| SCHEMBL13136963 | 0.82 | LMNA (0.54) | TAAR1LMNAQPCTCHEK1POLB | |
| Trifluoroacetic Acid SCHEMBL3041965 | 0.81 | HDAC1 (0.47) | — | |
| Trifluoroacetic Acid SCHEMBL3037461 | 0.81 | S1PR2 (0.38) | — | |
| Trifluoroacetic Acid SCHEMBL3051304 | 0.81 | MEN1 (0.44) | SNCAMEN1KMT2A | |
| Trifluoroacetic Acid SCHEMBL3047191 | 0.80 | HDAC1 (0.45) | POLB | |
| Trifluoroacetic Acid SCHEMBL3034897 | 0.80 | KDM4E (0.48) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222345-A1 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS | SMITHKLINE BEECHAM CORPORATION | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222345-A1 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS | OPRL1, OPRM1, OPRK1 | TAAR1 97/4885LMNA 4551/4885QPCT 1796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.